CORDIS
EU research results

CORDIS

English EN

Randomised controlled trial to evaluate electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for patients with cancers

Objective

The eSMART programme of work will demonstrate the effects of a real-time, mobile phone based, remote patient monitoring intervention on key patient outcomes and delivery of care provided to people with cancer during and after chemotherapy. Utilising the remote patient monitoring system, the Advanced Symptom Management System (ASyMS), will reduce the symptom burden experienced by patients receiving chemotherapy, improve their quality of life (QoL) during acute treatment and survivorship, and result in changes in clinical practice and improved delivery of care for patients with cancer. eSMART involves 11 European and one American partner as well as cancer care clinicians from all partner countries. A two-group, multicentre, repeated-measures randomised controlled trial (RCT) will be conducted across 16 sites in Europe, 1108 patients will be recruited. Adult (>18 years) patients diagnosed with breast, colorectal cancer or haematological cancers, commencing first-line chemotherapy and planned to receive at least 4 cycles of chemotherapy will be invited to participate. Work will take place in four consecutive phases. Members of the European Cancer Patient Coalition have an integral role as advisors at every stage of the programme to provide advice and feedback and ensure that work is conducted in line with patients’ perspectives and needs. eSMART will demonstrate how delivering patient focused, anticipatory care via technology can improve outcomes for people with cancer whilst simultaneously addressing the increasing demands on acute services across Europe by; enhancing patient outcomes and quality-of-life improvement; promoting of advances in cancer care; reducing social and economic barriers in cancer care; accelerating interoperability and collaboration across Europe and enhancing the economic stimulation of the National Health markets.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF STRATHCLYDE

Address

Richmond Street 16
G1 1xq Glasgow

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 973 659,05

Administrative Contact

David Mcbeth (Dr.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 537 118,17

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 923 469

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 670 747,08

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

United States

EU Contribution

€ 367 200

EUROPEAN CANCER PATIENT COALITION

Belgium

EU Contribution

€ 119 398,80

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 417 938,61

OSLO UNIVERSITETSSYKEHUS HF

Norway

NHS 24 (SCOTLAND)

United Kingdom

EU Contribution

€ 59 996

DOCOBO LTD

United Kingdom

EU Contribution

€ 449 130,38

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 101 176,80

SYKEHUSET INNLANDET HF

Norway

EU Contribution

€ 192 869,25

UNIVERSITY OF SURREY

United Kingdom

EU Contribution

€ 1 187 287,86

Project information

Grant agreement ID: 602289

Status

Closed project

  • Start date

    1 February 2014

  • End date

    31 January 2019

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 819 789,62

  • EU contribution

    € 5 999 991

Coordinated by:

UNIVERSITY OF STRATHCLYDE

United Kingdom